EDGAR Filing Documents for 0001104659-20-140170

Form 8-K - Current report:

SEC Accession No. 0001104659-20-140170

Filing Date

2020-12-29

Accepted

2020-12-29 16:38:18

Documents

Period of Report

2020-12-22

Items

Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 8-K	tm2039446d1_8k.htm	8-K	32637
2	EXHIBIT 3.1	tm2039446d1_ex3-1.htm	EX-3.1	47055
3	EXHIBIT 3.2	tm2039446d1_ex3-2.htm	EX-3.2	192411
4	EXHIBIT 99.1	tm2039446d1_ex99-1.htm	EX-99.1	9119
5	EXHIBIT 99.2	tm2039446d1_ex99-2.htm	EX-99.2	8963
	Complete submission text file	0001104659-20-140170.txt		291451

Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339

Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419

Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)